Docetaxel plus ramucirumab immediately after immunotherapy in advanced NSCLC: A phase II study (DRUN). | ClinicLens

Docetaxel plus ramucirumab is a standard second-line treatment for advanced non-small cell lung cancer (NSCLC). Prior immunotherapy has been suggested to potentially affect the efficacy of subsequent docetaxel plus ramucirumab, but prospective evidence is limited. This multicente

Medical Literature · Updated 2026-08-07

← Back to articles

This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.